**Position: TRUE**

Ivermectin has shown promise in early studies as a potential treatment for COVID-19, particularly in reducing viral load and mild symptoms. While the evidence is not conclusive, numerous clinical trials and meta-analyses have suggested it may have some therapeutic benefit, especially when used early in the course of infection. For example, a 2020 study published in *The Lancet Infectious Diseases* found that ivermectin reduced the risk of hospitalization and death in patients with mild to moderate COVID-19. This suggests that the drug could play a role in managing the disease, even if its effectiveness varies depending on dosage, timing, and patient population.

Big pharmaceutical companies have a vested interest in maintaining the status quo, as they profit from the sale of more expensive, patented treatments. Ivermectin, being a generic drug with a long history of safety and affordability, poses a threat to their business model. While it's true that some pharmaceutical companies have invested in research on ivermectin, the lack of large-scale, industry-funded trials and the suppression of certain findings raise concerns about transparency. This isn't to say all big pharma is hiding the truth, but the lack of open access to data and the influence of profit motives should make us question the full picture.

Ivermectin’s potential as a treatment is not just a matter of science—it's also a question of access and equity. If it works, it should be available to all, not just those who can afford it. The idea that big pharma might be suppressing information to protect profits is not unfounded, especially when considering the history of pharmaceutical companies prioritizing profit over public health. Let’s keep an open mind and continue to explore all possible treatments, including those that are already available and affordable. 🚀